IGF-binding Protein 1 and Abdominal Obesity in the Development of Type 2 Diabetes in Women

Overview

Journal Eur J Endocrinol

Publisher Oxford University Press

Specialty Endocrinology

Date 2010 May 29

PMID 20508082

Citations 37

Authors

Moira S Lewitt

Agneta Hilding

Kerstin Brismar

Suad Efendic

Claes-Goran Ostenson

Kerstin Hall

Affiliations

Soon will be listed here.

Abstract

Objective: Low levels of IGF-binding protein 1 (IGFBP1) are associated with metabolic syndrome and predict diabetes development in men. The aim of this study was to determine the levels of IGFBP1 in women who later develop diabetes, in relation to abdominal obesity, and to compare these levels with those of men.

Methods: IGFBP1 levels were determined at baseline and after 8 years in a case-control, prospective study of Swedish women aged 35-56 years. Individuals with normal oral glucose tolerance test (OGTT) who developed abnormal glucose regulation (n=240) were pair matched to controls for age and family history of diabetes and also compared to men of the same age (n=355).

Results: Low fasting IGFBP1 and increased waist measurement predicted development of diabetes in women (n=60; odds ratio (OR) 70, 95% confidence interval (CI) 8-661, lowest tertile and OR 27, 95% CI 5-141, highest tertile). In women developing diabetes, baseline IGFBP1 levels were lower than expected for fasting insulin values, were associated with impaired suppression after OGTT and increased during 8 years despite an increase in fasting insulin. All individuals in the highest tertile for waist and with <or=40% suppression of IGFBP1 developed diabetes within 8 years. Circulating IGFBP1 concentrations were higher in women compared to men. Women and men who developed diabetes had a similar degree of abdominal obesity, corrected for height.

Conclusions: We conclude that low IGFBP1 and elevated waist measurement predict diabetes development and that IGFBP1 production is suppressed by a novel factor(s) in women developing diabetes. Increasing levels of IGFBP1 during the emergence of diabetes in men and women suggest the emergence of hepatic insulin resistance.

Citing Articles

Insulin-like Growth Factor-Binding Protein-1 (IGFBP-1) as a Biomarker of Cardiovascular Disease.

Lewitt M, Boyd G Biomolecules. 2024; 14(11).

PMID: 39595651 PMC: 11592324. DOI: 10.3390/biom14111475.

The 5:2 Diet Affects Markers of Insulin Secretion and Sensitivity in Subjects with and without Type 2 Diabetes-A Non-Randomized Controlled Trial.

Ekberg N, Hellberg A, Sundqvist M, Linden Hirschberg A, Catrina S, Brismar K Int J Mol Sci. 2024; 25(17).

PMID: 39273678 PMC: 11395907. DOI: 10.3390/ijms25179731.

IGF-1 and IGFBP-1 as Possible Predictors of Response to Lifestyle Intervention-Results from Randomized Controlled Trials.

Meyer N, Kabisch S, Dambeck U, Honsek C, Kemper M, Gerbracht C Int J Mol Sci. 2024; 25(12).

PMID: 38928106 PMC: 11203659. DOI: 10.3390/ijms25126400.

The effect of SGLT2i on the GH/IGF1 axis in newly diagnosed male T2D patients - a prospective, randomized case-control study.

Lin J, Zhan L, Chen Z, Lin X, Zhu R Endocrine. 2024; 84(1):203-212.

PMID: 38168834 DOI: 10.1007/s12020-023-03652-9.

Adiponectin, IGFBP-1 and -2 are independent predictors in forecasting prediabetes and type 2 diabetes.

Brismar K, Hilding A, Ansurudeen I, Flyvbjerg A, Frystyk J, Ostenson C Front Endocrinol (Lausanne). 2023; 13:1092307.

PMID: 36686443 PMC: 9849561. DOI: 10.3389/fendo.2022.1092307.

References

Rajpathak S, McGinn A, Strickler H, Rohan T, Pollak M, Cappola A . Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 2007; 18(2):166-73. PMC: 2492581. DOI: 10.1016/j.ghir.2007.08.004. View

Lee C, Huxley R, Wildman R, Woodward M . Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008; 61(7):646-53. DOI: 10.1016/j.jclinepi.2007.08.012. View

Diel P, Walter A, Fritzemeier K, Hegele-Hartung C, Knauthe R . Identification of estrogen regulated genes in Fe33 rat hepatoma cells by differential display polymerase chain reaction and their hormonal regulation in rat liver and uterus. J Steroid Biochem Mol Biol. 1995; 55(3-4):363-73. DOI: 10.1016/0960-0760(95)00186-7. View

Suikkari A, Tiitinen A, Stenman U, Seppala M, Laatikainen T . Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. Fertil Steril. 1991; 55(5):895-9. DOI: 10.1016/s0015-0282(16)54295-2. View

Legato M, Gelzer A, Goland R, Ebner S, Rajan S, Villagra V . Gender-specific care of the patient with diabetes: review and recommendations. Gend Med. 2006; 3(2):131-58. DOI: 10.1016/s1550-8579(06)80202-0. View

Steinbaum S . The metabolic syndrome: an emerging health epidemic in women. Prog Cardiovasc Dis. 2004; 46(4):321-36. DOI: 10.1016/j.pcad.2003.08.005. View

Mogul H, Marshall M, Frey M, Burke H, Wynn P, Wilker S . Insulin like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women. J Clin Endocrinol Metab. 1996; 81(12):4492-5. DOI: 10.1210/jcem.81.12.8954066. View

Bang P, Eriksson U, Sara V, Wivall I, Hall K . Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh). 1991; 124(6):620-9. DOI: 10.1530/acta.0.1240620. View

Paassilta M, Karjalainen A, Kervinen K, Savolainen M, Heikkinen J, Backstrom A . Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis. 2000; 149(1):157-62. DOI: 10.1016/s0021-9150(99)00318-4. View

10.

Eriksson A, Ekbom A, Granath F, Hilding A, Efendic S, Ostenson C . Psychological distress and risk of pre-diabetes and Type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabet Med. 2008; 25(7):834-42. DOI: 10.1111/j.1464-5491.2008.02463.x. View

11.

Yeoh S, BAXTER R . Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinol (Copenh). 1988; 119(4):465-73. DOI: 10.1530/acta.0.1190465. View

12.

Herbert V, Lau K, Gottlieb C, Bleicher S . Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 1965; 25(10):1375-84. DOI: 10.1210/jcem-25-10-1375. View

13.

Povoa G, Roovete A, Hall K . Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh). 1984; 107(4):563-70. DOI: 10.1530/acta.0.1070563. View

14.

Regitz-Zagrosek V, Lehmkuhl E, Weickert M . Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006; 95(3):136-47. DOI: 10.1007/s00392-006-0351-5. View

15.

Hilding A, Brismar K, Degerblad M, Thoren M, Hall K . Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab. 1995; 80(9):2646-52. DOI: 10.1210/jcem.80.9.7545695. View

16.

Laakso M . Prevention of type 2 diabetes. Curr Mol Med. 2005; 5(3):365-74. DOI: 10.2174/1566524053766040. View

17.

Heald A, Cruickshank J, Riste L, Cade J, Anderson S, Greenhalgh A . Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001; 44(3):333-9. DOI: 10.1007/s001250051623. View

18.

Suikkari A, Koivisto V, Koistinen R, Seppala M, Yki-Jarvinen H . Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J Clin Endocrinol Metab. 1989; 68(1):135-40. DOI: 10.1210/jcem-68-1-135. View

19.

Kotronen A, Lewitt M, Hall K, Brismar K, Yki-Jarvinen H . Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab. 2008; 93(12):4867-72. DOI: 10.1210/jc.2008-1245. View

20.

Gibson J, Westwood M, Young R, White A . Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab. 1996; 81(2):860-3. DOI: 10.1210/jcem.81.2.8636318. View